Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #23 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Neuland Laboratories Limited (this stock) | 28,065 | 56.5 | 19.4% | 44.3% | 0.16% | 91 | 0 | 29 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 642 | 198 | 148 | ₹ |
| March 31, 2026 | 776 | 287 | 213 | ₹ |
| Dec. 31, 2025 | 440 | 54 | 41 | ₹ |
| Sept. 30, 2025 | 514 | 129 | 97 | ₹ |
| June 30, 2025 | 293 | 18 | 14 | ₹ |
| March 31, 2025 | 328 | 39 | 28 | ₹ |
| Dec. 31, 2024 | 398 | 128 | 102 | ₹ |
| Sept. 30, 2024 | 311 | 49 | 33 | ₹ |
| June 30, 2024 | 440 | 130 | 98 | ₹ |
| March 31, 2024 | 385 | 92 | 68 | ₹ |
| Dec. 31, 2023 | 393 | 104 | 81 | ₹ |
| Sept. 30, 2023 | 418 | 122 | 89 | ₹ |
| June 30, 2023 | 363 | 83 | 62 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 2,023 | 489 | 364 |
| March 31, 2025 | 1,477 | 346 | 260 |
| March 31, 2024 | 1,559 | 401 | 300 |
| March 31, 2023 | 1,191 | 216 | 164 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 347 | -424 | 21 | 390 | -43 |
| March 31, 2025 | 317 | -298 | 25 | 206 | 111 |
| March 31, 2024 | 261 | -150 | -69 | 141 | 120 |
| March 31, 2023 | 237 | -61 | -136 | 66 | 172 |
| March 31, 2022 | 59 | -94 | 38 | 96 | -37 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 2,930 | 1,874 | 1,862 | 36 | 161 | 1,483 | 710 | 77 | 892 | 510 |
| March 31, 2025 | 2,180 | 1,525 | 1,512 | 45 | 91 | 1,139 | 466 | 132 | 674 | 386 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2023 | — | — | — | — | — | — | — | — | — | — |
| March 31, 2022 | — | — | — | — | — | — | — | — | — | — |
